Niche Prostate Screening Soar BioDynamics focuses on a PSA-based smart screening approach for prostate cancer that aims to reduce unnecessary biopsies and late diagnoses, presenting a differentiated value proposition to patients and healthcare providers seeking improved screening outcomes.

Targeted Patient Story Founder background as a prostate cancer survivor and a mission-driven message may resonate with patient advocacy groups, urology clinics, and health systems looking for trusted, patient-centric screening narratives to bolster adoption.

Selective Revenue Potential Current revenue is under one million with a very small team, indicating an opportunity to scale through partnerships with clinics, laboratories, and digital health platforms that can integrate or white-label ProstateSmart screening services.

Tech-Enhanced Screening Combination of blood tests, imaging, and risk calculators positions the offering for integration with existing PSA workflows and imaging services, enabling cross-sell to labs, radiology centers, and primary care networks.

Strategic Partnerships With a focus on risk-adaptive testing and patient preferences, there is potential to partner with oncology and urology groups, health plans, and wellness platforms to expand access, drive referrals, and scale reach beyond direct consumer traffic.